Medical Condition News

RSS

Oakley grants $1 million to YSC to assist young women with breast cancer

Young Survival Coalition (YSC) is proud to announce that Oakley, Inc.'s support of YSC has exceeded $1 million. YSC is the premier global organization dedicated to providing education, resources and hope to young women who are diagnosed with breast cancer.

29 Sep 2010

Researchers identify biomarkers for mesothelioma and pancreatic cancer

Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer, pancreatic and mesothelioma.

29 Sep 2010

Saudi FDA approves Apligraf for treatment of diabetic foot ulcers, chronic wounds

Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia. Apligraf is a living cell based product used by physicians to heal chronic wounds in patients in the U.S. and around the world.

29 Sep 2010

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

HUYA Bioscience International, the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.

29 Sep 2010

SGC releases 1000th high resolution protein structure

The Structural Genomics Consortium (SGC), an international public private partnership that aims to determine three dimensional structures of medically important proteins, announced today the release into the public domain of its 1000th high resolution protein structure.

29 Sep 2010

c-Met could be a potential personalized target for metastatic HCC

Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

USFDA approves Sun Pharmaceutical's ANDA to market Rilutek tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.

29 Sep 2010

National survey shows 60% of U.S. adults not familiar with sepsis

Sixty percent of U.S. adults are not familiar with sepsis, despite the fact that more than 200,000 Americans die from it every year, making sepsis one of the leading causes of death in the nation. Lack of awareness is even higher among adults over age 65, who are at greater risk of sepsis, according to a new national survey sponsored by The Feinstein Institute for Medical Research in Manhasset, NY, part of the North Shore–LIJ Health System.

28 Sep 2010

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Afflicting countless people worldwide, chronic pain is a largely misunderstood and under-treated disease that forever alters the lives of more than 50 million Americans each year.

28 Sep 2010

Neuronix to present TMS treatment trial data for Alzheimer's disease at Geneva Congress

The results of a successful clinical trial using Neuronix Ltd., a developer of a patent-pending, non-invasive system for Alzheimer's Disease and related conditions, will be presented for the first time today at the annual Congress of the European Federation of Neurological Societies in Geneva, Switzerland.

28 Sep 2010

$IOF report reveals poor state of post-fracture care in Russian Federation$

IOF report reveals poor state of post-fracture care in Russian Federation

Preliminary findings from an upcoming new report by the International Osteoporosis Foundation (IOF) show alarming projections and reveal the poor state of post-fracture care in the Russian Federation and many other countries in the region. The findings were announced today at a press conference in St. Petersburg at the IOF Summit of Eastern European and Central Asian Osteoporosis Patient Societies.

28 Sep 2010

Researchers find genetic variants that cause arthritis in breast cancer patients taking aromatase inhibitors

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.

28 Sep 2010

NIH Stroke Scale helps to predict mortality risk in hospitalized stroke patients

A new study finds a risk model developed using Get With The Guidelines-Stroke data is a practical bedside tool that can identify patients at the highest risk for dying when hospitalized after a stroke.

28 Sep 2010

Optogenetics helps to restore optimal movement in people with physical disabilities

Researchers at Stanford University were able to use light to induce normal patterns of muscle contraction, in a study involving bioengineered mice whose nerve-cell surfaces are coated with special light-sensitive proteins.

28 Sep 2010

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Galapagos NV announced today that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis. In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011.

28 Sep 2010

Study confirms Artelon Cosmetic can treat patients with tissue defects

A post-market study has been conducted by the Brånemark Clinic in Gothenburg on Artelon Cosmetic for soft tissue augmentation in the upper jaw. The study confirms that patients with tissue defects can be treated successfully with Artelon Cosmetic.

28 Sep 2010

SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.

28 Sep 2010

Routine, short bouts of exercise can increase fitness levels

Trying to get fit but can't work it into your daily schedule? Incorporating even relatively short bouts of exercise into a daily commute appears to deliver significant rewards, according to a new study from the University of North Carolina at Chapel Hill.

28 Sep 2010

Study reveals hunger costs Minnesotans $1.62 billion per annum

A University of Minnesota Food Industry Center study funded by Target and released today reveals that hunger is costing Minnesotans upwards of $1.62 billion annually in direct and indirect health and education costs. The Cost/Benefit Study also suggests that interventions aimed at preventing hunger are sound moral, social and financial investments.

28 Sep 2010

Researchers develop microelectronic circuitry to guide axon growth in damaged brain

Researchers in the Midwest are developing microelectronic circuitry to guide the growth of axons in a brain damaged by an exploding bomb, car crash or stroke. The goal is to rewire the brain connectivity and bypass the region damaged by trauma, in order to restore normal behavior and movement.

28 Sep 2010